SOTAGLIFLOZIN SIGNIFICANTLY REDUCES CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN THE SCORED TRIAL
Therapeutic Area: Diabetes Background: SGLT2 inhibitors have had a remarkable effect on heart failure, but variable effects on ischemic endpoints. In the SCORED trial, sotagliflozin, a dual SGLT1 and 2 inhibitor, reduced total cardiovascular (CV) deaths, heart failure hospitalizations, and urgent he...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2023-03-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|